Formulary and subgroup decision updates

Following the February meeting of GMMMG, the formulary has been updated to reflect decisions made by the Clinical Reference Group (CRG) and Medicines and Guidelines Subgroup (MGSG). Changes include:

  • Addition of NICE guidance and MHRA drug safety updates to formulary
  • Duloxetine 90mg and 120mg capsules added to grey list as a GREEN drug
  • Insulin degludec added to grey list as a GREEN (specialist initiation) drug
  • Isoniazid for tuberculosis prophylaxis in renal patients added to RAG list as GREEN (specialist initiation)
  • Dapsone 50mg and 100mg tablets for PCP prophylaxis added to RAG list as GREEN (specialist initiation)

For full details of the changes, please see the Formulary Change Log.

Consultation: actions from February meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the February 2022 CRG meeting.

Actions in this consultation include:

  • Modafinil for narcolepsy and in Parkinson’s disease: GREEN following specialist initiation
  • Dacepton (apomorphine): AMBER; to be added to existing shared care protocol
  • Bempedoic acid: GREEN following specialist advice (previously specialist initiation)
  • Sotrovimab for COVID-19: RED
  • Mexiletine for myotonia: RED
  • Liraglutide for obesity in people aged 12-17: Do Not Prescribe
  • Dupilumab for severe asthma: RED
  • Belimumab for SLE: RED
  • Cenobamate for epilepsy: GREEN following specialist initiation (by a tertiary epilepsy service)
  • Risdiplam for spinal muscular atrophy: RED
  • Solriamfetol for narcolepsy: RED
  • Fostamatinib for chronic ITP: Do Not Prescribe

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 4th April 2022.

New consultations: high cost drugs pathways

Two new consultations have been opened on the GMMMG consultations page. The topics are:

  • High cost drugs pathway: psoriatic arthritis
  • High cost drugs pathway: axial spondyloarthritis

These consultations will be open until 5pm on Thursday 22nd March 2022, and comments are invited from all stakeholders.

GMMMG are mindful of additional service pressures at present therefore if you foresee any problems giving input on these consultations, or if you have any questions, please contact the secretariat at nuth.enquires.gmmmg@nhs.net.

New consultations: pathway updates and formulary amendments

A batch of new consultations has been opened on the GMMMG consultations page. The topics include:

  • Actions from the December meeting of CRG
  • Updated rheumatoid arthritis high cost drugs pathway
  • Updated neuropathic pain pathway
  • Updated headache pathway
  • Updated primary care rebate scheme ethical framework

Each of these consultations will be open until 5pm on Monday 14th February, and comments are invited from all stakeholders.

GMMMG are mindful of additional service pressures at present, therefore these consultations will run for eight weeks instead of the usual six. Every effort has been made to allow sufficient time for appropriate clinical input to these documents, but if you foresee any problems or have any questions please contact the secretariat at nuth.enquires.gmmmg@nhs.net.

Formulary and subgroup decision updates

Following the November meeting of GMMMG, the formulary has been updated to reflect decisions made by the Clinical Reference Group (CRG) and Medicines and Guidelines Subgroup (MGSG). Changes include:

  • Addition of NICE technology appraisals and MHRA drug safety updates to formulary
  • Ustekinumab dose escalation in inflammatory bowel disease commissioning statement updated to include latest evidence

For full details of the changes, please see the Formulary Change Log.

Consultation: actions from November meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2021 CRG meeting.

Actions in this consultation include:

  • Insulin aspart Sanofi (Trurapi) to be added to formulary as a GREEN drug and first line option for rapid acting insulin.
  • Haloperidol 500 microgram tablets to be DNP (criterion 2)
  • Berotralstat for hereditary angioedema to be added to the RAG list as a RED drug
  • Casirivimab/imdevimab (Ronapreve)® to be added to formulary as a RED drug, with link to NG191

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 23rd December 2021.

Consultation: Updated High Cost Drugs Pathway for Inflammatory Bowel Disease

On behalf of the GMMMG IBD working group, we now seek comments on this draft version of the updated GM high cost drug IBD pathway. This consultation period is open until 5pm on Wednesday 22nd December 2021.

Take part in this, and other open consultations, on the consultations home page.

GMMMG RSS feed

The URL for the GMMMG RSS feed changed when the website refreshed, and can now be found at: https://gmmmg.nhs.uk/feed/.

RSS is a way to view any news items published on the site, directly in the RSS reader of your choice. To add an RSS subscription in Outlook 2016:

  • When viewing your email account, find the RSS Subscriptions folder in the left hand menu
  • Right click RSS Subscriptions, and choose “Add a new RSS feed”.
  • Paste or type in the address, https://gmmmg.nhs.uk/feed/ then press add
  • A dialogue box will pop up: “Add this RSS Feed to Outlook?”; click yes
  • The RSS feed should now be included as a folder in your Outlook menus, and will update when news items are published.

If you have any questions or problems, please contact us at nuth.enquires.gmmmg@nhs.net.

Antimicrobial guidelines updated

Following review and discussion at the October meeting of MGSG, the Greater Manchester Antimicrobial Guidelines have been updated. The latest version is available from the clinical guidance and pathways page.

Consultation: actions from October meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the October 2021 CRG meeting.

Actions in this consultation include:

  • Inhaled colistimethate, dornase alfa and tobramycin for cystic fibrosis in children – RED. Repatriation should not be sought until a request to do so has been received from the specialist.
  • Bimekizumab for moderate to severe plaque psoriasis – RED.
  • Link to NG191, Managing COVID-19, to be added to formulary in chapter 2

To take part in this consultation, visit the consultations page. This consultation period is open until 5pm Tuesday 30th November 2021.